<DOC>
	<DOCNO>NCT01797107</DOCNO>
	<brief_summary>The purpose study evaluate effect Azasite patient corneal surface irregularity ( meibomian gland dysfunction ) .</brief_summary>
	<brief_title>Study Determine Effect Azasite Corneal Surface Irregularity</brief_title>
	<detailed_description>This single-center , randomize , vehicle-controlled , double-masked , clinical trial compare four week course Azasite ( azithromycin ophthalmic 1 % ) vehicle ( Durasite® ) patient MGD-related evaporative dry eye . All patient evaluate screening , baseline , two week , four week , six week . The primary outcome measure improvement , compare baseline , corneal irregularity measure topographically-derived value , Corneal Irregularity Measurement ( CIM ) . Secondary outcome measure global symptom score , tear film break time , meibomian gland secretion characteristic , best-corrected distance visual acuity , corneal staining , axial topography base astigmatism pattern , IOL Master keratometry . We enroll 60 eye 30 patient , patient randomly assign receive Azasite one eye vehicle ( Durasite® ) fellow eye .</detailed_description>
	<mesh_term>Azithromycin</mesh_term>
	<criteria>Ability provide inform consent prior enrollment study Patient ability follow study instruction comply study protocol Corneal irregularity measurement ( CIM ) &gt; 1.7 eye Nonatrophic meibomian gland dysfunction ( MGD ) define abnormal meibomian expression least 2 meibomian gland eyelid eye At least two symptom least moderate severity ( ≥ grade 2 , 0 3 scale ) define MGD Global Symptom Score ( Itching , Foreignbody sensation , Dryness , Burning , Lid swell ) Tear film break time &lt; 10 second Schirmer anesthesia &gt; 5 mm Best correct distance visual acuity ( BCDVA ) &gt; 20/100 Cicatricial atrophic meibomian gland dysfunction ( MGD ) Any corneal disease scar involve central 6 mm , include epithelial basement membrane dystrophy , Salzmann nodular degeneration , recurrent erosion , keratoconus ectasia Use azithromycin doxycycline within 1 month screen Topical ocular antibiotic , antihistamine , allergy , steroid medication within 2 week baseline ( 2 week washout screening allow ) Topical prostaglandin analogue use within 30 day study The anticipate use drop , gel ointment study period outside study protocol Use eye makeup study period Active ocular infection inflammation History herpetic eye disease neurotrophic keratitis Lid pathology ( except MGD blepharitis ) examiner feel may affect ocular surface Significant conjunctival scar ( ex . h/o SJS ) Pterygium Lacrimal punctal occlusion within 2 month screen Ocular surgery within 1 year screen Monocular patient Pregnant , breastfeeding , sexually active female use contraception Uncontrolled systemic disease Presence disease ( medical ocular ) , opinion investigator , may interfere study 's safety interpretation Known allergy study medication component Current enrollment investigational drug device study within 30 day screen study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Meibomian gland dysfunction</keyword>
</DOC>